Table 3. Immunophenotyping and ADCC.
| Subject | Treatment day | Immunophenotyping % NK cells | Cytolytic activity cG250-ADCC | Cytolytic activity ‘classic’ ADCC | NK activity |
|---|---|---|---|---|---|
| #01 | 0, 21, 76 | 5, 4, 4 | 16, 9, 10 | 40, 29, 27 | −, 5, 4 |
| #06 | 0, 21, 77 | 9, 9, 7 | 14, 14, 11 | 38, 32, 40 | 16, 19,− |
| #07 | 0, 21, 77 | 9, 11, 9 | 8, 16, 5 | 94, 100, 50 | −, 35, − |
| #09 | 0, 28, 77 | 7, 8, 11 | 1, 1, 2 | 45, 72, 49 | −, 24, 28 |
| #10 | 0, 21, 77 | 6, 5, 2 | 0, 1, 0 | 40, 32, 38 | −, −, − |
| #11 | 0, 21, 77 | 8, 8, 5 | 10, 7, 5 | 55, 42, 48 | −, −, − |
| #12 | 0, 21, 77 | ND | 3, 3, 2 | 32, 39, 36 | −, −, − |
| #13 | 0, 21, 78 | ND | 2, 2, 2 | 27, 27, 22 | −, −, − |
| #15 | 0, 21, 77 | ND | 3, 1, 1 | 20, 16, 21 | −, −, − |
| #16 | 0, 21, 78 | 14, 13, 10 | 14, 25, 26 | 37, 47, 50 | 4, 8, 6 |
| #18 | 0, 29, 85 | 1, 1, 1 | 0, 2, 0 | 49, 37, 15 | 0, 1, 0 |
| #19 | 0, 21, 77 | 6, 2, 1 | 1, 0, 0 | 34, 38, 9 | 0, 0, 0 |
| #20 | 0, 21, 77 | 1, 1, 2 | 1, 2, 3 | 2, 6, 8 | 0, 2, 1 |
| #21 | 0, 21, 77 | 12, 12, 7 | 4, 4, 3 | 25, 23, 17 | 5, 5, 3 |
| #22 | −7, 21, 77 | 7, 4, 5 | 15, 7, − | 31, 40, − | 29, 16, − |
| #24 | −8, 21, 77 | 9, 4, 4 | 6, 5, 5 | 55, 36, 41 | 17, 16, 45 |
| #25 | 0, 21, 77 | 7, 7, 5 | 14, 15, 18 | 32, 37, 36 | 24, 23, 38 |
| #26 | 0, 50, 78 | 6, 4, 13 | 0, 0, 3 | 16, 20, 40 | 3, 6, 20 |
| #27 | 0, 21, 77 | 5, 4, 5 | 7, 9, 11 | 44, 32, 32 | −, −, − |
| #28 | 0, 28, 84 | 2, 3, 3 | 0, 0, 0 | 24, 22, 19 | 4, 4, 4 |
| #29 | 0, 28, 78 | 1, 1, 2 | 0, 1, 2 | 9, 8, 17 | 0, 0, 1 |
NK=natural killer cell; ADCC=antibody-dependent cellular cytotoxicity; ND=no data; %NK cells=percentage NK cells of viable leucocytes. Cytolytic activities expressed as %WMSL at effector-to-target-ratio of 20 : 1.cG250-ADCC : cG250 mAb-induced cytolysis of G250-ligand-expressing target cell. ‘classic’-ADCC: anti-P815 Ab-induced cytolysis of P815 target cell (=positive control).
NK activity: cytolysis of NK-sensitive target cell K562.